In vitro study of GDNF release from biodegradable PLGA microspheres

Aubert-Pouëssel, Anne; Venier-Julienne, Marie-Claire; Clavreul, Anne; Sergent, Michelle; Jollivet, Christophe; Montero‐Menei, Claudia N.; Garcion, Emmanuel; Bibby, David C.; Meneï, Philippe; Benoit, Jean‐Pierre

doi:10.1016/j.jconrel.2003.12.012

Cited by 103 publications

(44 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, expectations concerning the delivery of therapeutic proteins have been limited by their fragile structure and the frequent administrations required (Yang et al, 1997;Lam et al, 2000;Sinha et al, 2003). To protect them from proteolysis, to allow for their sustained delivery and to enhance their therapeutic efficacy, their encapsulation in injectable, biodegradable microparticles has been explored (Pean et al, 1999;Rosa et al, 2000;Aubert-Pouessel et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

How to achieve sustained and complete protein release from PLGA-based microparticles?

Giteau

Venier-Julienne

Aubert-Pouëssel

et al. 2008

International Journal of Pharmaceutics

234

184

View full text Add to dashboard Cite

One of the most challenging tasks in the delivery of therapeutic proteins from PLGAbased microparticles is the sustained and complete release of the protein in its native form.The mechanisms responsible for incomplete protein release from these devices are numerous and complex; the beneficial effect of different formulations has often been evaluated in vitro.Strategies employed for overcoming protein destabilization during the release step are reviewed in this paper. Proteins have been protected in the deleterious environment by adding stabilizers to the formulation, or by modifying the protein or the polymer. Alternatively, some strategies have aimed at avoiding the formation of the destabilizing environment. As experimental conditions may influence the results from in vitro release studies, we initially report precautions to avoid adverse effects.

show abstract

Section: Introductionmentioning

confidence: 99%

How to achieve sustained and complete protein release from PLGA-based microparticles?

Giteau

Venier-Julienne

Aubert-Pouëssel

et al. 2008

International Journal of Pharmaceutics

234

184

View full text Add to dashboard Cite

show abstract

“…Numerous proteins have successfully been encapsulated into PLGA microspheres such as erythropoietin [9], growth hormone [10], interferon gamma [10], calcitonin [11], chorionic gonadotrophin [12], nerve growth factor [13], brain derived neurotrophic factor [14] or glial cell-line derived neurotrophic factor (GDNF) [15] among others.…”

Section: Introductionmentioning

confidence: 99%

Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres

Garbayo

Ansorena

Lanciego

et al. 2008

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

“…Plenaxis TM (abarelix for injectable suspension) is supplied as a white to off-white sterile dry powder which, when mixed with the diluent (0.9% Sodium Chloride Injection), becomes a depot suspension intended for intramuscular injection. Cetrotide TM (cetrorelix acetate for injection) 0.25 or 3 mg is a sterile lyophilized powder intended for subcutaneous injection after reconstitution with sterile water for injection (USP, pH [5][6][7][8]. Cetrotide TM may be administered subcutaneously either once daily (0.25 mg dose) or once (3 mg dose) during the early-to mid-follicular phase.…”

Section: Tmmentioning

confidence: 99%

“…Microspheres prepared from poly(DL-lactide-co-glycolide) (PLGA) polymers have been studied extensively in the last two decades as sustained release dosage forms. [5][6][7] PLGA is biocompatible, and more importantly, the degradation rates of PLGA and the accompanying release of encapsulated drugs can be controlled by the polymer's physicochemical properties such as molecular weight, hydrophilicity, and the ratio of lactide (LA) to glycolide (GA). 8,9) Thus, it is possible to obtain the desired drug release from PLGA microspheres by altering the polymer's characteristics.…”

mentioning

confidence: 99%

Biodegradable PLGA Microspheres as a Sustained Release System for a New Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist

Cheng

Chi

et al. 2006

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

A sustained release poly(DL-lactide-co-glycolide) (PLGA) microsphere delivery system to treat prostate cancer for a luteinizing hormone-releasing hormone (LHRH) antagonists, LXT-101 was prepared and evaluated in the paper. LXT-101 microspheres were prepared from PLGA by three methods: (1) double-emulsion solvent extraction/evaporation technique, (2) single-emulsion solvent extraction/evaporation technique, and (3) S/O/O (solid-in-oil-in-oil) method. The microspheres were investigated on drug loading, particle size, surface morphology and in vitro release profiles. An accelerated release approach was also established in order to expedite the evaluation periods. The in vivo evaluation of the microspheres was made by monitoring testosterone levels after subcutaneous administration to rats. The LXT-101 PLGA microspheres showed smooth and round surfaces according to a scanning electron microscopic investigation, and average particle size of ca. 30 m mm according to laser diffractometry. The drug encapsulation efficiency of microspheres was influenced by LA/GA ratio of PLGA, salt concentrations, solvent mixture and preparation methods. Moreover, LA/GA ratio of PLGA, different preparation methods and different peptide stabilizers affected in vitro release of drugs. In vivo study, the testosterone levels were suppressed to castration up to 42 d as for the 7.5 mg/kg dose. And in vivo performance of LXT-101 microspheres was dose-dependent. The weights of rat sexual organs decreased and histopathological appearance of testes had little changes after 4-month microspheres therapy. This also testified that LXT-101 sustained release microspheres could exert the efficacy to suppress the testosterone level to castration with little toxicity. In conclusion, the PLGA microspheres could be a well sustained release system for LXT-101.

show abstract

In vitro study of GDNF release from biodegradable PLGA microspheres

Cited by 103 publications

References 44 publications

How to achieve sustained and complete protein release from PLGA-based microparticles?

How to achieve sustained and complete protein release from PLGA-based microparticles?

Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres

Biodegradable PLGA Microspheres as a Sustained Release System for a New Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist

Contact Info

Product

Resources

About